e-learning
resources
London 2016
Tuesday, 06.09.2016
Biomarkers and phenotypes of COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Inflammatory markers (IL-6, suPAR) and arterial stiffness parameters in COPD patients
Renáta Marietta Böcskei (Budapest, Hungary), Renáta Marietta Böcskei, Lilla Tamási, Béla Benczúr, András Bikov, György Losonczy, Anikó Bohács
Source:
International Congress 2016 – Biomarkers and phenotypes of COPD
Session:
Biomarkers and phenotypes of COPD
Session type:
Thematic Poster
Number:
3670
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Renáta Marietta Böcskei (Budapest, Hungary), Renáta Marietta Böcskei, Lilla Tamási, Béla Benczúr, András Bikov, György Losonczy, Anikó Bohács. Inflammatory markers (IL-6, suPAR) and arterial stiffness parameters in COPD patients. Eur Respir J 2016; 48: Suppl. 60, 3670
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on acute decompensated pulmonary hypertension
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Association between adipokines, inflammatory markers and systemic manifestations in chronic obstructive pulmonary disease (COPD) patients
Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities
Year: 2016
COPD, an inflammatory systemic disease. Inflammatory parameters in a group of COPD patients
Source: International Congress 2014 – Lung function, COPD and inflammation
Year: 2014
Production of proinflammation cytokines and mean pulmonary arterial pressure in COPD
Source: Annual Congress 2013 –The vulnerable patient and ageing cells
Year: 2013
24-hour arterial stiffness monitoring values in patients with COPD
Source: Annual Congress 2013 –COPD: acute exacerbations and others
Year: 2013
Role of inflammatory biomarkers in COPD
Source: International Congress 2016 – Systemic biomarkers
Year: 2016
Microalbuminuria as a cardiovascular biomarker in patients with COPD
Source: International Congress 2016 – Systemic biomarkers
Year: 2016
Biomarkers in COPD exacerbation, the role of adiponectin
Source: International Congress 2014 – Predictors
Year: 2014
Fibrinogen and CRP biomarkers in patients with exacerbation of COPD group C and D
Source: International Congress 2014 – Systemic biomarkers for airway diseases
Year: 2014
Metabolic syndrome in patients with COPD and their association with systemic inflammation
Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease
Year: 2015
Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study
Source: Eur Respir J 2010; 35: 540-548
Year: 2010
Inflammatory biomarkers in patients with COPD and pulmonary hypertension (PH).
Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension
Year: 2019
Endothelial microparticles in sputum of COPD patients: A potential biomarker of disease
Source: International Congress 2015 – Systemic and airway biomarkers
Year: 2015
Cardiovascular risk, subclinical atherosclerosis and markers of systemic inflammation in patients with COPD and frequent exacerbator phenotype
Source: International Congress 2016 – Monitoring comorbidities
Year: 2016
Serum levels of leptin and visfatin in chronic obstructive pulmonary disease
Source: International Congress 2015 – Different data in COPD
Year: 2015
Burden of comorbidities and NT-proBNP concentrations in stable COPD patients
Source: Annual Congress 2013 –The latest insights in respiratory muscles, neuromuscular disease and comorbidities
Year: 2013
Blood eosinophils and outcomes in COPD
Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities
Year: 2016
Inflammatory markers and COPD phenotypes as predictors of COPD exacerbations
Source: Annual Congress 2013 –Investigating COPD in longitudinal studies
Year: 2013
Exacerbations in the subpopulations and intermediate outcome measures in COPD study (SPIROMICS, NHLBI) are associated with sputum eosinophilia but not blood eosinophilia
Source: International Congress 2016 – What's new in biomarker analysis?
Year: 2016
Biological and phenomenological markers of ageing in patients with COPD and their relationship to CT emphysema scores
Source: International Congress 2015 – Notable abstracts in COPD: variety
Year: 2015
Matrix metalloproteinase, hyaluronic acid and C-reactive protein: Are they really markers of lung obstruction at COPD but not cardiovascular comorbidity?
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept